摘要
目的:基于微炎症因子及血清铁参数、促红细胞生成素(EPO)水平变化探究罗沙司他胶囊在肾性贫血(RA)患者中的应用价值。方法:选取2019年1月-2021年1月于本院确诊的70例RA患者,采用简单随机分组将其分为观察组(n=35)和对照组(n=35)。对照组采用重组人促红细胞生成素注射液治疗,观察组采用罗沙司他胶囊口服治疗,均持续治疗8周。比较两组临床疗效。比较两组治疗前后红细胞计数(RBC)、血红蛋白(Hb)、红细胞比容(HCT)、EPO、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、血清铁蛋白(SF)、转铁蛋白(TRF)、总铁结合力(TIBC)及转铁蛋白饱和度(TSAT)水平。比较两组治疗期间不良反应发生情况。结果:观察组治疗总有效率为97.14%,高于对照组的82.86%(P<0.05)。治疗后,观察组RBC、Hb及HCT均高于对照组(P<0.05),而两组EPO水平比较,差异无统计学意义(P>0.05)。治疗后,观察组血清CRP、TNF-α及IL-6水平均低于对照组(P<0.05)。治疗后,观察组血清SF、TRF、TIBC及TSAT水平均高于对照组(P<0.05)。观察组治疗期间不良反应发生率为14.29%,与对照组的17.14%比较,差异无统计学意义(P>0.05)。结论:罗沙司他胶囊治疗RA的效果显著,可纠正患者贫血表现,降低微炎症因子及EPO水平,改善血清铁参数,治疗安全性高。
Objective:To explore the application value of Roxadustat Capsule in patients with renal anemia (RA) based on changes in levels of micro-inflammatory factors,serum iron parameters and erythropoietin (EPO).Method:A total of 70 RA patients diagnosed in our hospital from January 2019 to January 2021 were selected.They were divided into observation group (n=35) and control group (n=35) by simple random grouping.The control group was treated with Recombinant Human Erythropoietin Injection,and the observation group was treated with Roxadustat Capsule orally.Both groups were treated for 8 weeks.The clinical efficacy was compared between the two groups.Red blood cell count (RBC),hemoglobin (Hb),hematocrit (HCT),EPO,C-reactive protein (CRP),tumor necrosis factor-α (TNF-α),interleukin-6 (IL-6),serum ferrin (SF),transferrin (TRF),total iron binding capacity (TIBC) and transferrin saturation (TSAT) level were compared between two groups before and after treatment.The incidence of adverse reactions during treatment was compared between the two groups.Result:The total effective rate of the observation group was 97.14%,which was higher than 82.86% of the control group (P<0.05).After treatment,RBC,Hb and HCT in the observation group were higher than those in the control group (P<0.05),but there was no significant difference in EPO level between the two groups (P>0.05).After treatment,the serum CRP,TNF-α and IL-6 levels in observation group were lower than those in control group (P<0.05).After treatment,the levels of serum SF,TRF,TIBC and TSAT in observation group were higher than those in control group (P<0.05).The incidence of adverse reactions in the observation group during treatment was 14.29%,which was not statistically significant compared with 17.14% in the control group (P>0.05).Conclusion:Rosalastat Capsule has a significant effect in the treatment of RA,which can correct the symptoms of anemia in patients,reduce the levels of micro-inflammatory factors and EPO,and improve the serum iron parameters,with high therapeutic safety.
作者
李金花
魏林
朱璐
段志新
LI Jinhua;WEI Lin;ZHU Lu;DUAN Zhixin(Jiujiang Hospital of Traditional Chinese Medicine,Jiujiang 332000,China)
出处
《中国医学创新》
CAS
2021年第25期28-32,共5页
Medical Innovation of China
基金
江西省卫生健康委科技计划项目(202140382)。
作者简介
通信作者:李金花。
